Timing of SMA Therapies

Dr. Charlotte Sumner describes how early intervention is crucial when treating SMA.

I think another really important issue when considering a degenerative disorder like we're talking about in spinal muscular atrophy is the importance of trying to deliver in a timely fashion. That may relate to how of the neurons had been lost at the time that the treatment is delivered. We likely need to get in there at a time when neurons maybe dysfunctional but not all together gone. It may be quite difficult to reverse disorder once motor neurons have been lost in a profound way. So a very important issue for considering how best to do clinical trials with some of these very exciting new treatments is to consider trying to do things at least initially early in this disease. It prevents those motor neurons that are still there from dying and that would be an enormous benefit. So then you could expect that you would prevent progression of the disease, worsening of the disease over time because you arrest the ongoing loss of motor neurons. But it is also very possible that delivery even when motor neurons have already been lost will be very helpful for those motor neurons that remain. And maybe even allow them to function even better and make muscle a little stronger.

Spinal muscular atrophy, SMA, RNA, mRNA, splicing, gene, genetic, DNA, antisense, motor neuron, splice, Therapy, intervention, degenerative, Hopkins, john Hopkins,

Related Content

16950. 2D Animation of Antisense Oligonucleotide Therapy for SMA

An animation shows how antisense oligonucleotide therapy for SMA utilizes RNA splicing.

  • ID: 16950
  • Source: DNALC.SMA

16948. Alternative RNA Splicing Therapy for Spinal Muscular Atrophy

Drs. Sharp and Sumner describe how RNA splicing can be used as a therapy for SMA.

  • ID: 16948
  • Source: DNALC.SMA

16947. Small Molecule Therapy for SMA

Dr. Sumner describes small molecule therapies for SMA.

  • ID: 16947
  • Source: DNALC.SMA

16930. The Inheritance Pattern of SMA

Dr. Sumner describes how SMA is inherited.

  • ID: 16930
  • Source: DNALC.SMA

16952. 2D Animation of Intrathecal Drug Delivery for SMA

An animation shows how drugs for SMA may be delivered via infusion into the spinal cord.

  • ID: 16952
  • Source: DNALC.SMA

16941. 2D Animation of Alternative RNA Splicing

An animation shows alternate splicing of the SMN2 gene.

  • ID: 16941
  • Source: DNALC.SMA

16910. Cause of SMA

Dr. Sumner explains what causes SMA.

  • ID: 16910
  • Source: DNALC.SMA

16953. Gene Therapy for SMA

Dr. Sumner talks about gene therapy for SMA.

  • ID: 16953
  • Source: DNALC.SMA

16931. 2D Animation of Genes and Inheritance

An animation introduces DNA and the pattern of inheritance for SMA.

  • ID: 16931
  • Source: DNALC.SMA

16954. Clinical Trials for New SMA Therapies

Dr. Sumner discusses the clinical trial process for SMA antisense oligonucleotide therapy.

  • ID: 16954
  • Source: DNALC.SMA